Skip to main content
. 2024 Feb 15;73(6):124–130. doi: 10.15585/mmwr.mm7306a2

FIGURE 1.

This figure is a combination of a bar and line graph illustrating the number and percentage of 139,740 drug overdose deaths with evidence of selected routes of drug use for 28 U.S. jurisdictions by 6-month period of death, during January 2020–December 2022, based on data from the State Unintentional Drug Overdose Reporting System.

Number and percentage of drug overdose deaths with evidence of selected routes of drug use,*,† by 6-month period of death (N = 139,740) — State Unintentional Drug Overdose Reporting System, 28 jurisdictions,§, January 2020–December 2022

Abbreviation: SUDORS = State Unintentional Drug Overdose Reporting System.

* Percentages with evidence of other routes (i.e., buccal, sublingual, suppository, or transdermal) (583; 0.4%) are not presented because of small sample sizes; decedents with drug use via these routes are included in the denominators. In addition, percentages of decedents with no information on route (68,260; 48.8%) are not shown; these decedents are also included in the denominators.

† Routes of drug use are not mutually exclusive; decedents might have used multiple routes.

§ Alaska, Arizona, Colorado, Connecticut, Delaware, District of Columbia, Georgia, Illinois, Kansas, Kentucky, Maine, Maryland, Massachusetts, Minnesota, Nebraska, New Hampshire, New Jersey, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Utah, Vermont, Virginia, Washington, and West Virginia. Illinois and Washington reported deaths from counties that accounted for ≥75% of drug overdose deaths in the respective state in 2017, per SUDORS funding requirements; all other jurisdictions reported deaths from the full jurisdiction.

Jurisdictions were included if medical examiner or coroner reports and toxicology reports were available for ≥75% of deaths during January 2020–December 2022. Analysis was restricted to deaths with an available medical examiner or coroner report (139,740; 95.8% of all deaths).